Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address unmet medical needs in otolaryngology, has formed a drug discovery collaboration with King’s College London, UK. Professor David Thurston of the Institute of Pharmaceutical Science will lead a team at King’s to develop and optimize a range of specific small molecules for Auris Medical’s AM-102 project. The AM-102 compounds bind to a novel, undisclosed drug target for treating ce...